Total Payments
$507,440
2024 Payments
$9,806
Companies
38
Transactions
855
Medicare Patients
13,519
Medicare Billing
$1.2M
Payment Breakdown by Category
Other$423,504 (83.5%)
Travel$52,685 (10.4%)
Food & Beverage$20,261 (4.0%)
Consulting$7,850 (1.5%)
Research$2,990 (0.6%)
Education$150.04 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $418,504 | 163 | 82.5% |
| Travel and Lodging | $52,685 | 110 | 10.4% |
| Food and Beverage | $20,261 | 567 | 4.0% |
| Consulting Fee | $7,850 | 3 | 1.5% |
| Honoraria | $5,000 | 1 | 1.0% |
| Unspecified | $2,990 | 5 | 0.6% |
| Education | $150.04 | 6 | 0.0% |
Payments by Type
General
$504,450
850 transactions
Research
$2,990
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $265,871 | 381 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $145,640 | 147 | $0 (2024) |
| GENZYME CORPORATION | $74,363 | 64 | $0 (2024) |
| Amgen Inc. | $6,368 | 15 | $0 (2024) |
| DAVOL INC. | $5,000 | 1 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $3,552 | 35 | $0 (2024) |
| Eli Lilly and Company | $2,990 | 5 | $0 (2024) |
| Janssen Biotech, Inc. | $1,336 | 88 | $0 (2024) |
| Lilly USA, LLC | $324.23 | 17 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $280.55 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,806 | 61 | ABBVIE INC. ($5,463) |
| 2023 | $39,403 | 88 | Regeneron Healthcare Solutions, Inc. ($15,443) |
| 2022 | $41,265 | 65 | ABBVIE INC. ($19,384) |
| 2021 | $30,309 | 40 | AbbVie Inc. ($19,495) |
| 2020 | $28,263 | 47 | AbbVie Inc. ($16,198) |
| 2019 | $104,929 | 192 | AbbVie, Inc. ($66,486) |
| 2018 | $119,216 | 172 | Regeneron Healthcare Solutions, Inc. ($52,064) |
| 2017 | $134,250 | 190 | AbbVie, Inc. ($79,217) |
All Payment Transactions
855 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Food and Beverage | In-kind items and services | $23.82 | General |
| Category: Immunology | ||||||
| 12/12/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $29.26 | General |
| Category: Dermatology | ||||||
| 11/20/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $12.76 | General |
| Category: IMMUNOLOGY | ||||||
| 11/18/2024 | Galderma Laboratories, L.P. | DYSPORT (Biological) | Food and Beverage | In-kind items and services | $20.67 | General |
| 11/08/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: Immunology | ||||||
| 11/06/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $20.59 | General |
| Category: Dermatology | ||||||
| 11/01/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,725.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/25/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $18.31 | General |
| Category: Immunology | ||||||
| 10/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: Immunology | ||||||
| 10/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $20.89 | General |
| Category: IMMUNOLOGY | ||||||
| 09/27/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/25/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $28.80 | General |
| Category: Dermatology | ||||||
| 09/23/2024 | Eli Lilly and Company | TALTZ (Drug) | — | In-kind items and services | $104.58 | Research |
| Study: EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) • Category: Immunology | ||||||
| 09/20/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $14.55 | General |
| 09/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,725.00 | General |
| Category: IMMUNOLOGY | ||||||
| 09/18/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: Dermatology | ||||||
| 09/06/2024 | Lilly USA, LLC | OLUMIANT (Drug) | Food and Beverage | In-kind items and services | $24.52 | General |
| Category: Immunology | ||||||
| 09/04/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: Dermatology | ||||||
| 08/30/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: Immunology | ||||||
| 08/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $0.40 | General |
| Category: IMMUNOLOGY | ||||||
| 08/15/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $6.51 | General |
| Category: IMMUNOLOGY | ||||||
| 08/15/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $1.31 | General |
| Category: IMMUNOLOGY | ||||||
| 08/14/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: IMMUNOLOGY | ||||||
| 08/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $33.74 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | Eli Lilly and Company | $2,886 | 4 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $104.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 3,185 | 6,076 | $567,553 | $269,879 |
| 2022 | 27 | 3,366 | 6,428 | $589,316 | $285,674 |
| 2021 | 31 | 3,654 | 6,965 | $690,758 | $335,990 |
| 2020 | 27 | 3,314 | 5,951 | $607,545 | $294,999 |
Total Patients
13,519
Total Services
25,420
Medicare Billing
$1.2M
Procedure Codes
110
All Medicare Procedures & Services
110 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 976 | 1,390 | $185,426 | $87,872 | 47.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 379 | 449 | $68,819 | $33,330 | 48.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 539 | 718 | $72,316 | $30,551 | 42.2% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 82 | 125 | $31,773 | $16,330 | 51.4% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 21 | 47 | $25,728 | $14,235 | 55.3% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 435 | 2,378 | $23,849 | $12,589 | 52.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 102 | 116 | $21,856 | $9,798 | 44.8% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 53 | 64 | $17,211 | $8,359 | 48.6% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 106 | 171 | $12,964 | $7,330 | 56.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 66 | 79 | $13,546 | $7,040 | 52.0% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 23 | 25 | $11,461 | $6,338 | 55.3% |
| 11301 | Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2023 | 48 | 70 | $12,922 | $5,153 | 39.9% |
| 96567 | Application of light to destroy precancer skin growth | Office | 2023 | 19 | 40 | $8,519 | $4,403 | 51.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 56 | 56 | $9,287 | $4,170 | 44.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 90 | 97 | $8,137 | $3,951 | 48.6% |
| 17272 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2023 | 20 | 26 | $7,370 | $3,418 | 46.4% |
| 11302 | Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 37 | 39 | $8,083 | $3,367 | 41.7% |
| 11311 | Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | Office | 2023 | 24 | 26 | $5,369 | $2,467 | 45.9% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2023 | 17 | 18 | $7,561 | $2,287 | 30.2% |
| 10060 | Simple or single drainage of skin abscess | Office | 2023 | 18 | 18 | $3,395 | $1,748 | 51.5% |
| 69100 | Biopsy of ear | Office | 2023 | 25 | 28 | $4,068 | $1,514 | 37.2% |
| 17261 | Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | Office | 2023 | 11 | 14 | $3,123 | $1,278 | 40.9% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 12 | 12 | $2,275 | $1,200 | 52.7% |
| 96900 | Application of ultraviolet light to skin | Office | 2023 | 13 | 35 | $1,290 | $594.72 | 46.1% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 13 | 35 | $1,206 | $555.52 | 46.0% |
About Dr. Jonathan Wolfe, MD
Dr. Jonathan Wolfe, MD is a Procedural Dermatology healthcare provider based in Plymouth Meeting, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1235142084.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Wolfe, MD has received a total of $507,440 in payments from pharmaceutical and medical device companies, with $9,806 received in 2024. These payments were reported across 855 transactions from 38 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($418,504).
As a Medicare-enrolled provider, Wolfe has provided services to 13,519 Medicare beneficiaries, totaling 25,420 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 110 distinct procedure/service records.
Ad
Practice Information
- Specialty Procedural Dermatology
- Location Plymouth Meeting, PA
- Active Since 08/14/2006
- Last Updated 07/08/2007
- Taxonomy Code 207NS0135X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1235142084
Products in Payments
- Humira (Biological) $139,944
- DUPIXENT DUPILUMAB INJECTION (Biological) $90,318
- DUPIXENT (Biological) $87,077
- SKYRIZI (Biological) $58,763
- DUPIXENT (Drug) $32,752
- Skyrizi (Biological) $30,534
- ATOPIC DERMATITIS - DISEASE (Drug) $9,801
- HUMIRA (Biological) $8,729
- RINVOQ (Biological) $6,424
- Enbrel (Biological) $6,241
- ARISTA AH (Device) $5,000
- COSENTYX (Biological) $3,459
- Tremfya (Drug) $438.15
- STELARA (Biological) $392.11
- TALTZ (Drug) $338.98
- REMICADE (Biological) $327.84
- TREMFYA (Drug) $301.75
- ILUMYA (Biological) $243.63
- VTAMA (Drug) $175.11
- OPZELURA (Drug) $170.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.